GLAXOSMITHKLINE IS ONE OF CANADA'S LARGEST RESEARCH-BASED PHARMACEUTICAL COMPANIES. GLAXOSMITHKLILNE OPERATES FOUR MAIN FACILITIES IN CANADA, INCLUDING ITS HEAD OFFICE AND MANUFACTURING OPERATIONS IN MISSISSAUGA, AND ITS BUREAU D'AFFAURES DU QUEBEC IN MONTREAL. IN TOTAL GLAXOSMITHKLINE EMPLOYS APPROXIMATELY 1,800 PEOPLE ACROSS THE COUNTRY. GSK IS A LEADER IN MANY IMPORTANT THERAPEUTIC AREAS, INCLUDING RESPIRATORY, CENTRAL NERVOUS SYSTEM, ANTI-INFECTIVES AND GASTRO INTESTINAL/METABOLIC. GLAXOSMITHKLINE INVESTS MORE THAN $100 MILLION IN RESEARCH & DEVELOPMENT IN CANADA EACH YEAR. GLAXOSMITHKLINE'S $120 MILLION MANUFACTURING OPERATIONS PRODUCE MORE THAN 100 MEDICINES AND 20 MILLION UNITS ANNUALLY.
Paul Lucas, President and Chief Executive Officer
End date of the last completed financial year: 2011-12-31
Government Institution | Funding Received in Last Financial Year | Funding Expected in Current Financial Year |
---|---|---|
Ontario Innovation Biopharmaceutical Investment Program (BiP) program | $3,577,140.00 | No |
Address:
7333 Mississauga Road
Mississauga, ON L5N 6L4
Canada
Telephone number:
905-819-3000
Fax number:
905-819-3099